Drug Search Results
More Filters [+]

Eftrenonacog alfa

Alternative Names: eftrenonacog alfa, alprolix
Latest Update: 2024-09-19
Latest Update Note: Clinical Trial Update

Product Description

Eftrenonacog alfa (Alprolix™) is a recombinant fusion protein comprising human factor IX (FIX) covalently linked to the constant region (Fc) domain of human IgG1 (i.e. rFIXFc). The presence of the Fc domain extends the terminal half-life (t½) of rFIXFc, permitting prolonged treatment intervals. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/28646426/)

Mechanisms of Action: FIX Cleaver

Novel Mechanism: Yes

Modality: Coagulation Factor

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Australia | Austria | Belgium | Chile | Colombia | Croatia | Cyprus | Denmark | France | Germany | Hong Kong | Hungary | Iceland | Israel | Italy | Japan | Netherlands | New Zealand | Norway | Portugal | Saudi Arabia | Spain | Taiwan | Turkey | United Arab Emirates | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Eftrenonacog alfa

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Hemophilia A|Hemophilia

Phase 3: Hemophilia A|Hemophilia B

Phase 1: Hemophilia A|Menorrhagia|Hemophilia B

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Sobi.HAEM89-007

P4

Not yet recruiting

Hemophilia A

2025-11-15

OPTI-CLOT: TARGET

P4

Active, not recruiting

Hemophilia

2025-05-07

CHALE

N/A

Recruiting

Hemophilia B|Hemophilia A

2024-06-01

B-MORE

N/A

Completed

Hemophilia B|Hemophilia A

2024-03-12

Recent News Events